Progesterone Containing Contraceptive Methods on Endogenous Progesterone Level

Tanta University

Status: Completed

Conditions: Progesterone; Contraceptive Methods

Treatments: Other: Depo-Provera; Other: Mirena; Other: Implanon; Other: Norgestrel

Study type: Observational

Funder types: Other

Identifiers

NCT05742503

36035/11/22

Details and patient eligibility

About

The aim of this study is to assess the effect of different progesterone containing contraceptive methods on safety and endogenous progesterone level

Full description

Progestogen-only' contraceptives are presented as injections, implants, oral formulations, hormone-releasing intrauterine methods and emergency contraceptives. These substances could be used by females who are breastfeeding or have other contraindications to estrogen treatment, including those who are immediately postpartum, have thalassemia, sickle-cell disease, gallbladder disease, or currently experiencing thrombo-embolic disorders, valvular heart disease, ischemic heart disease.

Intrauterine, injectable methods and contraceptive implants named as long-acting reversible contraceptives (LARC) are the more efficient reversible contraceptive approaches are highly effective, longer-acting contraceptive methods levels.

Enrollment: 80 patients

Sex: Female

Ages: 20 to 35 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 80 healthy fertile females
• 20-35 years
• With normal menstrual history
• Had at least one offspring after spontaneous pregnancy

Exclusion criteria

• Any disease affects uterus (uterine tumors fibroids, endometriosis, prolapse, or tuberculosis).
• Ovarian tumors
• submucous myoma
• irregular menstrual cycle
• past or family history of breast disease
• Diabetic patients,
• medication affecting reproductive or metabolic functions.
• endometrial thickness <7 mm on the secretory transformation day
• history of spontaneous abortions
• history of embryo transfer failure on over three occasions
• Patients had cortisol medications
• patients who received radiological treatment

Trial design

80 participants in 4 patient groups

Depo-Provera group

Description:

This group will receive150 mg of injectable progesterone every 90 days or 3 months

Treatment:

Other: Depo-Provera

Implanon group

Description:

This group will receive 68 mg of etonogestrel implant formerly known as Implanon.

Treatment:

Other: Implanon

Norgestrel group

Description:

This group will receive 0.075 mg of norgestrel (Ovrette®) once daily.

Treatment:

Other: Norgestrel

Mirena group

Description:

This group will receive IUD (Mirena) containing 52 mg of levonorgestrel.

Treatment:

Other: Mirena